WOODCLIFF LAKE, N.J.
, Jan. 16, 2014
Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin®
(digoxin) Tablets. The Lanoxin®
brand has been relied upon for its quality and availability for more than 50 years. Digoxin tablets are indicated for treatment of mild to moderate heart failure in adults; increasing myocardial contractility in pediatric patients with heart failure; and control of resting ventricular rate in patients with chronic atrial fibrillation in adults.
Par has begun shipping 0.125 mg and 0.25 mg strengths of digoxin tablets. According to IMS Health data, annual U.S. sales of digoxin tablets are approximately $44 million.
Important Information About Digoxin Tablets
Digoxin tablets are contraindicated in patients with ventricular fibrillation and in patients with a known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). A hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. For full prescribing information, please visit www.parpharm.com.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit www.parpharm.com.
About Covis Pharma
Headquartered in Zug, Switzerland, Covis Pharma S.a.r.l. is a global specialty pharmaceutical company providing therapeutic solutions to patients. The company's distinctive product portfolio addresses life threatening and other serious medical conditions. For more information, visit www.covispharma.com.
SOURCE Par Pharmaceutical Companies, Inc.